{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["5(2)"],"submitter":["Garg AD"],"pubmed_abstract":["The emerging role of the cancer cell-immune cell interface in shaping tumorigenesis/anticancer immunotherapy has increased the need to identify prognostic biomarkers. Henceforth, our primary aim was to identify the immunogenic cell death (ICD)-derived metagene signatures in breast, lung and ovarian cancer that associate with improved patient survival. To this end, we analyzed the prognostic impact of differential gene-expression of 33 pre-clinically-validated ICD-parameters through a large-scale meta-analysis involving 3,983 patients ('discovery' dataset) across lung (1,432), breast (1,115) and ovarian (1,436) malignancies. The main results were also substantiated in 'validation' datasets consisting of 818 patients of same cancer-types (i.e. 285 breast/274 lung/259 ovarian). The ICD-associ"],"journal":["Oncoimmunology"],"pagination":["e1069938"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4801472"],"repository":["biostudies-literature"],"pubmed_title":["Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies: A large-scale meta-analysis."],"pmcid":["PMC4801472"],"pubmed_authors":["Garg AD","Agostinis P","De Ruysscher D"],"additional_accession":[]},"is_claimable":false,"name":"Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies: A large-scale meta-analysis.","description":"The emerging role of the cancer cell-immune cell interface in shaping tumorigenesis/anticancer immunotherapy has increased the need to identify prognostic biomarkers. Henceforth, our primary aim was to identify the immunogenic cell death (ICD)-derived metagene signatures in breast, lung and ovarian cancer that associate with improved patient survival. To this end, we analyzed the prognostic impact of differential gene-expression of 33 pre-clinically-validated ICD-parameters through a large-scale meta-analysis involving 3,983 patients ('discovery' dataset) across lung (1,432), breast (1,115) and ovarian (1,436) malignancies. The main results were also substantiated in 'validation' datasets consisting of 818 patients of same cancer-types (i.e. 285 breast/274 lung/259 ovarian). The ICD-associ","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Feb","modification":"2026-05-04T01:06:20.306Z","creation":"2019-03-27T03:09:57Z"},"accession":"S-EPMC4801472","cross_references":{"pubmed":["27057433"],"doi":["10.1080/2162402X.2015.1069938","10.1080/2162402x.2015.1069938"]}}